Balance Sheet Components

3 Months Ended

Mar. 31, 2022

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

Balance Sheet Components

Cash, Cash Equivalents and Restricted Cash

A reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is as follows (in thousands):

	March 31, 2022		March 31, 2021
Cash and cash equivalents	$	109,872	$	148,113
Restricted cash	1,499		1,499
Total cash, cash equivalents and restricted cash	$	111,371	$	149,612

Property and Equipment

Property and equipment consisted of the following (in thousands):

	March 31, 2022		December 31, 2021
Leasehold improvements	$	25,880	$	25,880
Laboratory equipment and office furniture	22,227		21,916
Computer equipment	1,253		1,225
Construction-in-progress	399		18
Total property and equipment, gross	49,759		49,039
Less: accumulated depreciation and amortization	(40,323)		(38,968)
Total property and equipment, net	$	9,436	$	10,071

Depreciation expense was $1.4 million and $1.6 million for the three months ended March 31, 2022 and 2021, respectively.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2022		December 31, 2021
Clinical trials and research and development costs	$	13,671	$	12,070
Personnel-related costs	5,768		10,298
Manufacturing costs	4,667		7,773
Accrued expenses	5,372		3,117
Total accrued liabilities	$	29,478	$	33,258